Related references
Note: Only part of the references are listed.Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA
David M. Kurtz et al.
NATURE BIOTECHNOLOGY (2021)
Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma
Karthik Nath et al.
BLOOD ADVANCES (2021)
Prognostic value of FDG-PET in patients with mantle cell lymphoma: results from the LyMa-PET Project
Clement Bailly et al.
HAEMATOLOGICA (2020)
The development of liquid biopsy for research and clinical practice in lymphomas: Report of the 15-ICML workshop on ctDNA
Davide Rossi et al.
HEMATOLOGICAL ONCOLOGY (2020)
Bortezomib consolidation or maintenance following immunochemotherapy and autologous stem cell transplantation for mantle cell lymphoma: CALGB/Alliance 50403
Lawrence D. Kaplan et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial
Jeanette K. Doorduijn et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Plasma or Serum: Which Is Preferable for Mutation Detection in Liquid Biopsy?
Fabio Pittella-Silva et al.
CLINICAL CHEMISTRY (2020)
Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes
Ferran Nadeu et al.
BLOOD (2020)
Analytical evaluation of the clonoSEQ Assay for establishing measurable (minimal) residual disease in acute lymphoblastic leukemia, chronic lymphocytic leukemia, and multiple myeloma
Travers Ching et al.
BMC CANCER (2020)
Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study
Zachary D. Epstein-Peterson et al.
BLOOD (2020)
A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
Remy Gressin et al.
HAEMATOLOGICA (2019)
Prognostic Value of Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma Reply
David M. Kurtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma
Domenico Albano et al.
ANNALS OF NUCLEAR MEDICINE (2019)
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction
David M. Kurtz et al.
CELL (2019)
Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
Rishu Agarwal et al.
NATURE MEDICINE (2019)
Surveillance imaging in mantle cell lymphoma in first remission lacks clinical utility
Daniel M. Guidot et al.
LEUKEMIA & LYMPHOMA (2018)
A gene signature that distinguishes conventional and leukemic nonnodal mantle cell lymphoma helps predict outcome
Guillem Clot et al.
BLOOD (2018)
Efficacy and safety of frontline rituximab, cyclophosphamide, doxorubicin and prednisone plus bortezomib (VR-CAP) or vincristine (R-CHOP) in a subset of newly diagnosed mantle cell lymphoma patients medically eligible for transplantation in the randomized, phase 3 LYM-3002 study
Johannes Drach et al.
LEUKEMIA & LYMPHOMA (2018)
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
David M. Kurtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study
Tadeusz Robak et al.
LANCET ONCOLOGY (2018)
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study
Gregor Verhoef et al.
HAEMATOLOGICA (2017)
New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies
David W. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma
S. Le Gouill et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study
Gregor Verhoef et al.
HAEMATOLOGICA (2017)
Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years
Arne Kolstad et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for newly diagnosed mantle cell lymphoma: SWOG S0601
Brian G. Till et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma
Nakhle S. Saba et al.
BLOOD (2016)
15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau
Christian W. Eskelund et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma
Philippe Armand et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
Olivier Hermine et al.
LANCET (2016)
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
Florian Scherer et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
David M. Kurtz et al.
BLOOD (2015)
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study
Mark Roschewski et al.
LANCET ONCOLOGY (2015)
Bortezomib-Based Therapy for Newly Diagnosed Mantle-Cell Lymphoma
Tadeusz Robak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0
Ronald Boellaard et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders
M. Ladetto et al.
LEUKEMIA (2014)
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909
Hongtao Liu et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Treatment of Older Patients with Mantle-Cell Lymphoma
H. C. Kluin-Nelemans et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era
Patricia Perez-Galan et al.
BLOOD (2011)
Prognostic impact of proliferative index determined by quantitative image analysis and the International Prognostic Index in patients with mantle cell lymphoma
R. Schaffel et al.
ANNALS OF ONCOLOGY (2010)
Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study
Christiane Pott et al.
BLOOD (2010)
Time to Treatment Does Not Influence Overall Survival in Newly Diagnosed Mantle-Cell Lymphoma
Heather E. Eve et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Peter Martin et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue:: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
Christian H. Geisler et al.
BLOOD (2008)
Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-Cell lymphoma with analysis of germinal center and post-germinal center biomarkers
Wyndham H. Wilson et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Rituximab-EPOCH, an efective front-line therapy for mantle cell lymphoma
Andres Palacios et al.
BLOOD (2007)
Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
C Pott et al.
BLOOD (2006)
High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
JE Romaguera et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma
SS Neelapu et al.
NATURE MEDICINE (2005)
The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma
A Rosenwald et al.
CANCER CELL (2003)
Share Paper
